Forus Health's 3nethra Neo To Screen Prematurely Born Babies For A Condition That Affects Eyes
Lightweight, easily portable, handheld, rugged and highly cost effective is how one would describe the 3nethra Neo, a Retinopathy of Prematurity (ROP) imaging platform, developed by Bengaluru based Forus Health.
3nethra Neo screens prematurely born babies who could potentially have retinopathy of prematurity, a condition wherein abnormal blood vessels grow in the retina, the layer in the eye that enables us to see. This condition can result in permanent blindness of the child, if not detected and treated very early. "The real motivation was to save the eyes of a baby. You are also touching a very important emotional quotient of the parent. As for the business case, there was only one player, we felt there was a need for our product," said K Chandrasekhar, CEO of Forus Health. Forus Health had won the Social Enterprise award in last year's ET Startup Awards.
3nethra Neo screens prematurely born babies who could potentially have retinopathy of prematurity, a condition wherein abnormal blood vessels grow in the retina, the layer in the eye that enables us to see. This condition can result in permanent blindness of the child, if not detected and treated very early. "The real motivation was to save the eyes of a baby. You are also touching a very important emotional quotient of the parent. As for the business case, there was only one player, we felt there was a need for our product," said K Chandrasekhar, CEO of Forus Health. Forus Health had won the Social Enterprise award in last year's ET Startup Awards.